Navigation Links
Glucose: Potential new target for combating annual seasonal influenza

Reducing glucose metabolism dials down influenza viral infection in laboratory cell cultures, providing an entirely new approach for combating seasonal flu, according to research that will be presented on Sunday, Dec. 15, at the American Society for Cell Biology (ASCB) annual meeting in New Orleans.

While annual flu shots are based on the U.S. Centers for Disease Control (CDC)'s predictions of the viruses that will be in widest circulation each flu season, the new approach targets one metabolic requirement of all influenza viruses: glucose.

Reducing viruses' glucose supply weakens the microbes' ability to infect host cells, said Amy Adamson, Ph.D., and Hinissan Pascaline Kohio of the University of North Carolina, Greensboro.

Fever, ache, and the other miseries of influenza viral infection afflict 5 to 20 percent of the U.S. population each year. While the flue is usually not life-threatening to the majority of its victims, the Spanish flu pandemic of 1918 demonstrated that flu viruses can evolve into lethal agents that spread worldwide. Because flu viruses change continually through mutation and genetic swaps, the CDC reformulates the flu vaccine each year

Yet to infect cells, the influenza virus is dependent upon the actions of the cell's own proteins, and so another strategy for slowing viral infection would be to target essential viral needs, for example, their dependence on cellular glucose. Dr. Adamson and Kohio showed that influenza A infection can be controlled in laboratory cultures of mammalian cells by altering glucose metabolism.

When the influenza virus initially infects a cell, and the virus is confined in an endocytic vesicle, the viral proteins HA and M2 use the acidic environment inside the vesicle to fuse the viral lipid envelope with that of the vesicle, and then release the viral genome into the cytosol. The acidic pH that mediates these important viral process is established and maintained by the cell's vacuolar-type H+ ATPase (V-ATPase) proton pump. The researchers found that this dependence could be used to manipulate the infection's success.

Dr. Adamson and Kohio boosted glucose concentrations in the laboratory cell cultures, and influenza infection rate concomitantly increased. Treating the viral cells with a chemical that inhibits glucose metabolism significantly decreased viral replication in the lab cultures. The researchers also demonstrated that the infection could be restored to high levels simply by adding ATP, the major source of energy for cellular reactions, bypassing the need for glucose.

Looking closer, they discovered that higher levels of glucose promoted the assembly of the V-ATPase proton pump that drives the release of the influenza A genome into the cytoplasm, the internal watery environment of the cell.

When Dr. Adamson and Kohio added the glucose inhibitor to the cell cultures, the assembly of the molecular pump was suppressed. Viral infection, they concluded, was closely tied to the assembly of the V-ATPase pump, and this dependence could be used to manipulate infection success.

Specifically, they were able to suppress viral infection of cells by dismantling the V-ATPase through the lowering of glucose levels. In addition, they inhibited infection by treating cells with chemical inhibitors of glycolysis, the initial pathway of glucose catabolism. Conversely, influenza viral infection of cells could be increased by giving cells more glucose than normal, the researchers report in the journal Virology,

The ease with which the researchers could dial viral infection down by controlling glucose levels and thus V-ATPase activity suggested a new strategy for throttling influenza viral infection.

"Taken together, we propose that altering glucose metabolism may be a potential new approach to inhibit influenza viral infection," said Dr. Adamson and Kohio.


Contact: Cathy Yarbrough

John Fleischman

American Society for Cell Biology

Related biology news :

1. Wayne State discovers potential treatment for skin and corneal wound healing in diabetics
2. Scientists identified T372R mutation as potential target for diagnosis and treatment of insulinoma
3. Morphing material has mighty potential
4. Study examines potential evolutionary role of sexual regret in human survival and reproduction
5. Biometric-Mobile Wallet Technology Takes Aims at a Target Market Of Nearly $1Billion Potential
6. New research finds potential risk for millions in Africa believed resistant to vivax malaria
7. Potential drug target in sight for rare genetic disease
8. Researcher finds potential new use for old drugs
9. Bold new partnership launches to harness potential of data scientists and big data
10. Research reveals new understanding, warning signs, and potential treatments for multiple sclerosis
11. Research points to potential window for treating CMV and preventing mother-to-child transmission
Post Your Comments:
(Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 ... an innovator in modern authentication and a founding member ... launch of its latest version of the Nok Nok™ ... to use standards-based authentication that supports existing and emerging ... Suite is ideal for organizations deploying customer-facing applications that ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... United Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt ... biopharmaceutical company, announced today that it has closed the ... (CMDS) business to Guerbet (GBT- NYSE Euronext) in a ... operations encompassed four manufacturing facilities and a total of ... 75 in the St. Louis ...
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
Breaking Biology Technology: